Handbook of Pharmaceutical Science and Technology Studies
Will be published approx. on 28. August 2026
Book
Hardback
600 pages
978-1-0353-3844-3 (ISBN)
Description
This comprehensive Handbook examines innovation in the pharmaceutical sector using ideas drawn from the interdisciplinary field of science and technology studies (STS). Leading experts present diverse social science approaches to pharmaceuticals, consolidating existing research and providing an agenda for future research in this area.
International contributors critically analyse the global dynamics of knowledge production, the political economy of manufacturing, the making of markets, their regulation and governance, and the diverse ecologies of consumption for pharmaceuticals. The Handbook deconstructs the constituent parts that make up the social, political and economic power of the pharmaceutical sector while also foregrounding alternatives to the dominant mode of innovation and production.
The Handbook of Pharmaceutical Science and Technology Studies is an essential resource for students and scholars in STS, economics, innovation and technology, health and social policy. It is also a valuable read for policymakers, professionals and practitioners involved in global bio-pharma innovation.
International contributors critically analyse the global dynamics of knowledge production, the political economy of manufacturing, the making of markets, their regulation and governance, and the diverse ecologies of consumption for pharmaceuticals. The Handbook deconstructs the constituent parts that make up the social, political and economic power of the pharmaceutical sector while also foregrounding alternatives to the dominant mode of innovation and production.
The Handbook of Pharmaceutical Science and Technology Studies is an essential resource for students and scholars in STS, economics, innovation and technology, health and social policy. It is also a valuable read for policymakers, professionals and practitioners involved in global bio-pharma innovation.
More details
Series
Language
English
Place of publication
Cheltenham
United Kingdom
Target group
Professional and scholarly
Dimensions
Height: 244 mm
Width: 169 mm
ISBN-13
978-1-0353-3844-3 (9781035338443)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Persons
Edited by Conor M.W. Douglas, Associate Professor, Department of Science, Technology and Society, York University, Canada, Susi Geiger, Professor of Markets, Organisations and Society, School of Business, University College Dublin, Tineke Kleinhout-Vliek, Researcher in Pharmaceutical Market Contestation, School of Business, University College Dublin, Ireland, Paul Martin, Professor, School of Sociological Studies, Politics and International Relations, University of Sheffield, UK and Sarah Wadmann, Senior Researcher, VIVE - Danish Center for Social Science Research, Denmark
Content
Contents
Introduction to the Handbook of Pharmaceutical Science and Technology Studies xviii
Conor Douglas, Susi Geiger, Tineke Kleinhout-Vliek, Paul Martin and Sarah Wadmann
PART I THE DEVELOPMENT OF PHARMACEUTICALS
1 The production of pharmaceutical knowledge 2
Paul Martin
2 Myths about innovation in the pharmaceutical industry 8
Joel Lexchin
3 From bench to bedside and back again 25
Joshua R. Moon
4 Population-making in the regulatory arenas of clinical trials 41
Jakob Wested
5 The dynamics of "Orphanization" and the move towards precision
medicine 57
Paul Martin, Andy Bartlett, Jin Ding, Matthew S. Hanchard and Eva Hilberg
6 How can innovation policy address "market failures" in the development of
novel medicines? 70
Jin Ding, Michael M. Hopkins and Jorge Mestre-Ferrandiz
7 Social pharmaceutical innovation (SPIN): A sensitizing concept for
challenges in rare diseases 90
Conor M. W. Douglas, Tineke Kleinhout-Vliek, Rob Hagendijk, Wouter
Boon, Claudio Cordovil Oliveira, Ellen Moors, Shir Grunebaum and
Fernando Aith
PART II MANUFACTURING AND PRODUCTION OF PHARMACEUTICALS
8 Introduction to Part II: The political economy of the manufacturing and
production of pharmaceuticals 111
Conor M. W. Douglas
9 Vaccine nationalism beyond COVID-19: Prior dynamics and subsequent
effects 121
Vesna Trifunovic, Jan Hendriks and Stuart Blume
10 Peripheral vaccine promises in Latin America: Expectations, coalitions,
and sovereignty 138
Gabriela Bortz, Maria Cecilia Sanmartin and Elize Massard da Fonseca
11 A world of generics: The manufacturing and circulation of generic
medicines worldwide 159
Etienne Nouguez
12 Manufacturing and production of advanced therapies: A case of blurred
boundaries 172
Michael Morrison, Isabel Briz Hernandez and Conor M. W. Douglas
13 Between activism and entrepreneurship: Challenging epistemic authority
through pharmaceutical peer production 190
Bianca Jansky, Shane O'Donnell, Henriette Langstrup and Muireann Quigley
14 Drugged ecologies: The case of pharmaceutical pollution 204
Gergely Mohacsi
PART III PHARMACEUTICAL MARKETIZATION: HOW MARKETS IN
PHARMA ARE MADE AND SHAPED
15 Pharmaceutical marketization: How markets in pharma are made and
shaped 223
Susi Geiger
16 The financialization of the pharmaceutical industry: the case of Novo
Nordisk's Wegovy 232
Prof Joan Busfield
17 "The price that we pay is not the real price of the medicine": How the
pharmaceutical price architecture facilitates financial accumulation 249
Susi Geiger and Theo Bourgeron
18 Medical writing, the marketing playbook, and the pharmaceutical industry 264
Maud Bernisson, Willem Halffman and Sergio Sismondo
19 The work digital does in pharmaceutical markets 281
Gemma Milne and Mathias Mollebaek
20 Pharmaceuticals from and for the Global South 298
Jean-Paul Gaudilliere and Fanny Chabrol
PART IV REGULATION AND GOVERNANCE OF PHARMACEUTICALS
21 "Regimes of pharmaceutical governance" 315
Tineke Kleinhout-Vliek
22 Expedited pathways in drug regulation: Evidence, uncertainty, and
acceleration in biomedical innovation 324
Mathias Mollebaek
23 From unmet medical needs to dilemmas of access to treatment: the case of
rare diseases and orphan drugs 337
Carlos Novas
24 The (ill)logics of patient engagement in drug development and evaluation 349
Olga Zvonareva and Hadewych Honne
25 Preventing, detecting, and responding to falsified and substandard
medicines 372
Raffaella Ravinetto, Amalia Hasnida and Koen Peeters Grietens
26 Universal aspirations and contextual decisions: The Essential Medicines
List and Health Technology Assessment 391
Tineke Kleinhout-Vliek and Susi Geiger
PART V USE AND MISUSE OF PHARMACEUTICALS
27 Ecologies of pharmaceutical consumption 408
Sarah Wadmann
28 De/prescribing matters: Ecologies of prescribing and deprescribing in
Science and Technology Studies 419
Lisa Lehner, Honja Hama, Igor Grabovac and Janina Kehr
29 Ecologies of resistance: The biosocial worlds of antibiotics 442
Joyce Sauann Lu and Omar Dewachi
30 Precision medicine and the reconfiguration of clinical practice and
patienthood 462
Sarah Wadmann, Amalie Martinus Hauge, Anna Brueckner Johansen
and Laura Emdal Navne
31 Beyond lay pharmacology: Fugitive, alternative, and pluralistic
pharmacologies as collective practice 482
Magdalena Goralska, Anthony Rizk and Nayantara Sheoran Appleton
32 Pharmaceutical leakage: The porous interplay between legal and illegal
opioid markets 497
Anne M. Lovell and Nancy D. Campbell
33 The food challenge to pharma: the unexplored potential of food drugs 512
Stephanie A. Nairn
PART VI AFTERWORD
34 Reflections: Pharmaceuticals and biotechnologies through STS lenses 529
Sergio Sismondo
Introduction to the Handbook of Pharmaceutical Science and Technology Studies xviii
Conor Douglas, Susi Geiger, Tineke Kleinhout-Vliek, Paul Martin and Sarah Wadmann
PART I THE DEVELOPMENT OF PHARMACEUTICALS
1 The production of pharmaceutical knowledge 2
Paul Martin
2 Myths about innovation in the pharmaceutical industry 8
Joel Lexchin
3 From bench to bedside and back again 25
Joshua R. Moon
4 Population-making in the regulatory arenas of clinical trials 41
Jakob Wested
5 The dynamics of "Orphanization" and the move towards precision
medicine 57
Paul Martin, Andy Bartlett, Jin Ding, Matthew S. Hanchard and Eva Hilberg
6 How can innovation policy address "market failures" in the development of
novel medicines? 70
Jin Ding, Michael M. Hopkins and Jorge Mestre-Ferrandiz
7 Social pharmaceutical innovation (SPIN): A sensitizing concept for
challenges in rare diseases 90
Conor M. W. Douglas, Tineke Kleinhout-Vliek, Rob Hagendijk, Wouter
Boon, Claudio Cordovil Oliveira, Ellen Moors, Shir Grunebaum and
Fernando Aith
PART II MANUFACTURING AND PRODUCTION OF PHARMACEUTICALS
8 Introduction to Part II: The political economy of the manufacturing and
production of pharmaceuticals 111
Conor M. W. Douglas
9 Vaccine nationalism beyond COVID-19: Prior dynamics and subsequent
effects 121
Vesna Trifunovic, Jan Hendriks and Stuart Blume
10 Peripheral vaccine promises in Latin America: Expectations, coalitions,
and sovereignty 138
Gabriela Bortz, Maria Cecilia Sanmartin and Elize Massard da Fonseca
11 A world of generics: The manufacturing and circulation of generic
medicines worldwide 159
Etienne Nouguez
12 Manufacturing and production of advanced therapies: A case of blurred
boundaries 172
Michael Morrison, Isabel Briz Hernandez and Conor M. W. Douglas
13 Between activism and entrepreneurship: Challenging epistemic authority
through pharmaceutical peer production 190
Bianca Jansky, Shane O'Donnell, Henriette Langstrup and Muireann Quigley
14 Drugged ecologies: The case of pharmaceutical pollution 204
Gergely Mohacsi
PART III PHARMACEUTICAL MARKETIZATION: HOW MARKETS IN
PHARMA ARE MADE AND SHAPED
15 Pharmaceutical marketization: How markets in pharma are made and
shaped 223
Susi Geiger
16 The financialization of the pharmaceutical industry: the case of Novo
Nordisk's Wegovy 232
Prof Joan Busfield
17 "The price that we pay is not the real price of the medicine": How the
pharmaceutical price architecture facilitates financial accumulation 249
Susi Geiger and Theo Bourgeron
18 Medical writing, the marketing playbook, and the pharmaceutical industry 264
Maud Bernisson, Willem Halffman and Sergio Sismondo
19 The work digital does in pharmaceutical markets 281
Gemma Milne and Mathias Mollebaek
20 Pharmaceuticals from and for the Global South 298
Jean-Paul Gaudilliere and Fanny Chabrol
PART IV REGULATION AND GOVERNANCE OF PHARMACEUTICALS
21 "Regimes of pharmaceutical governance" 315
Tineke Kleinhout-Vliek
22 Expedited pathways in drug regulation: Evidence, uncertainty, and
acceleration in biomedical innovation 324
Mathias Mollebaek
23 From unmet medical needs to dilemmas of access to treatment: the case of
rare diseases and orphan drugs 337
Carlos Novas
24 The (ill)logics of patient engagement in drug development and evaluation 349
Olga Zvonareva and Hadewych Honne
25 Preventing, detecting, and responding to falsified and substandard
medicines 372
Raffaella Ravinetto, Amalia Hasnida and Koen Peeters Grietens
26 Universal aspirations and contextual decisions: The Essential Medicines
List and Health Technology Assessment 391
Tineke Kleinhout-Vliek and Susi Geiger
PART V USE AND MISUSE OF PHARMACEUTICALS
27 Ecologies of pharmaceutical consumption 408
Sarah Wadmann
28 De/prescribing matters: Ecologies of prescribing and deprescribing in
Science and Technology Studies 419
Lisa Lehner, Honja Hama, Igor Grabovac and Janina Kehr
29 Ecologies of resistance: The biosocial worlds of antibiotics 442
Joyce Sauann Lu and Omar Dewachi
30 Precision medicine and the reconfiguration of clinical practice and
patienthood 462
Sarah Wadmann, Amalie Martinus Hauge, Anna Brueckner Johansen
and Laura Emdal Navne
31 Beyond lay pharmacology: Fugitive, alternative, and pluralistic
pharmacologies as collective practice 482
Magdalena Goralska, Anthony Rizk and Nayantara Sheoran Appleton
32 Pharmaceutical leakage: The porous interplay between legal and illegal
opioid markets 497
Anne M. Lovell and Nancy D. Campbell
33 The food challenge to pharma: the unexplored potential of food drugs 512
Stephanie A. Nairn
PART VI AFTERWORD
34 Reflections: Pharmaceuticals and biotechnologies through STS lenses 529
Sergio Sismondo